zonisamide has been researched along with Disease Models, Animal in 38 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Zonisamide is an antiepileptic drug with multiple mechanisms of action, corresponding to efficacy in diverse epilepsy syndromes." | 8.86 | Zonisamide in the treatment of epilepsy. ( Schulze-Bonhage, A, 2010) |
| "The present findings revealed that zonisamide treatment prevented the development of seizures in animals." | 7.88 | A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures. ( Attri, SV; Kumar, B; Medhi, B; Modi, M; Patial, A; Saikia, B, 2018) |
| "In this study, we investigated the effect of a novel antiepileptic drug, zonisamide (ZNS), on the basilar artery and hippocampus in a rabbit subarachnoid hemorrhage (SAH) model." | 7.79 | Study the effects of zonisamide on fine structure of rabbit basilar artery and hippocampus in rabbit subarachnoid hemorrhage model. ( Arikok, AT; Bavbek, M; Besalti, O; Caliskan, M; Demirci, AY; Seckin, H; Yigitkanli, K; Yigitkanli, T, 2013) |
| "To examine the mechanisms underlying the anti-tremor effect of zonisamide in rats under conditions of tacrine-induced tremulous jaw movements (TJMs)." | 7.75 | Effects of zonisamide on c-Fos expression under conditions of tacrine-induced tremulous jaw movements in rats: a potential mechanism underlying its anti-parkinsonian tremor effect. ( Kondo, T; Kubo, T; Miwa, H; Suzuki, A, 2009) |
| "Cervical spondylotic myelopathy (CSM) is caused by chronic compression of the spinal cord and is the most common cause of myelopathy in adults." | 5.56 | Zonisamide ameliorates progression of cervical spondylotic myelopathy in a rat model. ( Imagama, S; Inoue, T; Ishiguro, N; Ito, M; Kanbara, S; Koshimizu, H; Masuda, A; Nakashima, H; Ohkawara, B; Ohno, K; Ohta, K; Tomita, H, 2020) |
| "The zonisamide-treated group received an intraperitoneal injection of zonisamide." | 5.40 | Zonisamide attenuates hyperoxia-induced apoptosis in the developing rat brain. ( Bayram, E; Karaoğlu, P; Kumral, A; Kurul, SH; Ozbal, S; Topçu, Y; Tuğyan, K; Yılmaz, O; Yiş, U, 2014) |
| "Minimal clonic seizures were not suppressed by zonisamide." | 5.36 | Zonisamide suppresses the tonic phase but not the clonic phase of generalized seizures in developing rats. ( Mareš, P, 2010) |
| " Zonisamide is an antiepileptic drug with multiple mechanisms of action, corresponding to efficacy in diverse epilepsy syndromes." | 4.86 | Zonisamide in the treatment of epilepsy. ( Schulze-Bonhage, A, 2010) |
| "Zonisamide (ZNS) is a broad-spectrum antiepileptic drug in both animal models of epilepsy and patients with epilepsy." | 4.80 | Zonisamide. ( Leppik, IE, 1999) |
| "The present findings revealed that zonisamide treatment prevented the development of seizures in animals." | 3.88 | A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures. ( Attri, SV; Kumar, B; Medhi, B; Modi, M; Patial, A; Saikia, B, 2018) |
| "The anti-epileptic agent zonisamide (ZNS) has been shown to exert protective effects in neurotoxin-based mouse models of Parkinson disease." | 3.80 | Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease. ( Arawaka, S; Fukushima, S; Kato, T; Koga, K; Koyama, S; Sasaki, A; Sato, H, 2014) |
| "In this study, we investigated the effect of a novel antiepileptic drug, zonisamide (ZNS), on the basilar artery and hippocampus in a rabbit subarachnoid hemorrhage (SAH) model." | 3.79 | Study the effects of zonisamide on fine structure of rabbit basilar artery and hippocampus in rabbit subarachnoid hemorrhage model. ( Arikok, AT; Bavbek, M; Besalti, O; Caliskan, M; Demirci, AY; Seckin, H; Yigitkanli, K; Yigitkanli, T, 2013) |
| " Antiepileptics (carbamazepine, sodium valproate, zonisamide, clobazam, and topiramate), which are used for complex partial epilepsy or secondary generalized epilepsy in clinical practice, were orally administrated to kindled rats." | 3.76 | The usefulness of olfactory bulb kindling as a model for evaluation of antiepileptics. ( Akagi, M; Fujiwara, A; Ishikawa, T; Kaida, Y; Kamei, C; Takechi, K; Watanabe, Y, 2010) |
| "To examine the mechanisms underlying the anti-tremor effect of zonisamide in rats under conditions of tacrine-induced tremulous jaw movements (TJMs)." | 3.75 | Effects of zonisamide on c-Fos expression under conditions of tacrine-induced tremulous jaw movements in rats: a potential mechanism underlying its anti-parkinsonian tremor effect. ( Kondo, T; Kubo, T; Miwa, H; Suzuki, A, 2009) |
| " We have evaluated the effects and investigated the possible mechanisms of action of zonisamide, an antiepileptic drug, on thermal hyperalgesia and tactile allodynia in a murine chronic pain model that was prepared by partial ligation of the sciatic nerve." | 3.73 | Centrally mediated antihyperalgesic and antiallodynic effects of zonisamide following partial nerve injury in the mouse. ( Honda, M; Ono, H; Sakaue, A; Takasu, K; Tanabe, M, 2005) |
| "Cervical spondylotic myelopathy (CSM) is caused by chronic compression of the spinal cord and is the most common cause of myelopathy in adults." | 1.56 | Zonisamide ameliorates progression of cervical spondylotic myelopathy in a rat model. ( Imagama, S; Inoue, T; Ishiguro, N; Ito, M; Kanbara, S; Koshimizu, H; Masuda, A; Nakashima, H; Ohkawara, B; Ohno, K; Ohta, K; Tomita, H, 2020) |
| "Cellular mechanisms underlying neuropathic pain remain mostly elusive, and partial pain relief can be achieved in a limited number of patients by antidepressants, anticonvulsants topical anesthetics, and others." | 1.56 | Zonisamide ameliorates neuropathic pain partly by suppressing microglial activation in the spinal cord in a mouse model. ( Imagama, S; Inoue, T; Ishiguro, N; Ito, M; Kanbara, S; Kiryu-Seo, S; Kiyama, H; Konishi, H; Koshimizu, H; Masuda, A; Nakashima, H; Ohkawara, B; Ohno, K; Ota, K; Sayo, A; Tomita, H, 2020) |
| " Pronounced threshold increases were observed following administration of a constant zonisamide dosage combined with different doses of perampanel." | 1.43 | Synergism of perampanel and zonisamide in the rat amygdala kindling model of temporal lobe epilepsy. ( Komori, T; Potschka, H; Rettenbeck, ML; Russmann, V; Salvamoser, JD, 2016) |
| "Zonisamide has been reported to have protective effects on epilepsy and Parkinson׳s disease and to work via various mechanisms of action, such as inhibition of monoamine oxidase-B and enhancement of tyrosine hydroxylase." | 1.42 | Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo. ( Hara, H; Hashizume, T; Ishisaka, M; Shimazawa, M; Tsujii, S, 2015) |
| "The zonisamide-treated group received an intraperitoneal injection of zonisamide." | 1.40 | Zonisamide attenuates hyperoxia-induced apoptosis in the developing rat brain. ( Bayram, E; Karaoğlu, P; Kumral, A; Kurul, SH; Ozbal, S; Topçu, Y; Tuğyan, K; Yılmaz, O; Yiş, U, 2014) |
| "Zonisamide is an antiepileptic drug that also improves the cardinal symptoms of Parkinson's disease." | 1.37 | Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity. ( Choudhury, ME; Kubo, M; Kyaw, WT; Matsuda, S; Moritoyo, T; Nagai, M; Nishikawa, N; Nomoto, M; Yabe, H, 2011) |
| "Zonisamide treatment alone did not produce any lasting effects on ex vivo MAO-B activity, indicating that it is a reversible inhibitor of the enzyme." | 1.36 | The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. ( Buckley, B; Sonsalla, PK; Winnik, B; Wong, LY, 2010) |
| "Essential tremor is a common disorder that lacks molecular targets for therapeutic development." | 1.36 | T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor. ( Covey, DF; Handforth, A; Homanics, GE; Krishnan, K; Lee, JY; Martin, FC; Quesada, A; Sakimura, K, 2010) |
| "Minimal clonic seizures were not suppressed by zonisamide." | 1.36 | Zonisamide suppresses the tonic phase but not the clonic phase of generalized seizures in developing rats. ( Mareš, P, 2010) |
| "Zonisamide (ZNS) is a new AED effective in the treatment of refractory epilepsy and since it is only prescribed in polytherapy regimens, its interactions with other AEDs is of particular importance." | 1.34 | Interactions between zonisamide and conventional antiepileptic drugs in the mouse maximal electroshock test model. ( Borowicz, KK; Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N; Sobieszek, G, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.89) | 18.2507 |
| 2000's | 11 (28.95) | 29.6817 |
| 2010's | 21 (55.26) | 24.3611 |
| 2020's | 3 (7.89) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, T | 3 |
| Yajima, N | 3 |
| Tanitame, A | 1 |
| Kiyoshi, T | 3 |
| Miura, Y | 3 |
| Iwama, S | 2 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Kanbara, S | 2 |
| Ohkawara, B | 2 |
| Nakashima, H | 2 |
| Ohta, K | 1 |
| Koshimizu, H | 2 |
| Inoue, T | 2 |
| Tomita, H | 2 |
| Ito, M | 2 |
| Masuda, A | 2 |
| Ishiguro, N | 2 |
| Imagama, S | 2 |
| Ohno, K | 2 |
| Ota, K | 1 |
| Sayo, A | 1 |
| Kiryu-Seo, S | 1 |
| Konishi, H | 1 |
| Kiyama, H | 1 |
| Kumar, B | 1 |
| Medhi, B | 1 |
| Modi, M | 1 |
| Saikia, B | 1 |
| Attri, SV | 1 |
| Patial, A | 1 |
| Demirci, AY | 1 |
| Seckin, H | 1 |
| Besalti, O | 1 |
| Arikok, AT | 1 |
| Yigitkanli, T | 1 |
| Caliskan, M | 1 |
| Yigitkanli, K | 1 |
| Bavbek, M | 1 |
| Bektas, N | 1 |
| Arslan, R | 1 |
| Ozturk, Y | 1 |
| Arawaka, S | 1 |
| Fukushima, S | 1 |
| Sato, H | 1 |
| Sasaki, A | 1 |
| Koga, K | 1 |
| Koyama, S | 1 |
| Kato, T | 1 |
| Topçu, Y | 1 |
| Bayram, E | 1 |
| Ozbal, S | 1 |
| Yiş, U | 1 |
| Tuğyan, K | 1 |
| Karaoğlu, P | 1 |
| Kumral, A | 1 |
| Yılmaz, O | 1 |
| Kurul, SH | 1 |
| Tsujii, S | 1 |
| Ishisaka, M | 1 |
| Shimazawa, M | 1 |
| Hashizume, T | 1 |
| Hara, H | 1 |
| Russmann, V | 1 |
| Salvamoser, JD | 1 |
| Rettenbeck, ML | 1 |
| Komori, T | 1 |
| Potschka, H | 1 |
| Miwa, H | 1 |
| Kubo, T | 1 |
| Suzuki, A | 1 |
| Kondo, T | 1 |
| Yang, LP | 1 |
| Perry, CM | 1 |
| Fujiwara, A | 1 |
| Watanabe, Y | 1 |
| Takechi, K | 1 |
| Ishikawa, T | 1 |
| Kaida, Y | 1 |
| Akagi, M | 1 |
| Kamei, C | 1 |
| Sonsalla, PK | 1 |
| Wong, LY | 1 |
| Winnik, B | 1 |
| Buckley, B | 1 |
| Schulze-Bonhage, A | 1 |
| Asanuma, M | 1 |
| Miyazaki, I | 1 |
| Diaz-Corrales, FJ | 1 |
| Kimoto, N | 1 |
| Kikkawa, Y | 1 |
| Takeshima, M | 1 |
| Miyoshi, K | 1 |
| Murata, M | 1 |
| Yokoyama, H | 2 |
| Yano, R | 2 |
| Kuroiwa, H | 2 |
| Tsukada, T | 2 |
| Uchida, H | 2 |
| Kato, H | 2 |
| Kasahara, J | 2 |
| Araki, T | 2 |
| Handforth, A | 1 |
| Homanics, GE | 1 |
| Covey, DF | 1 |
| Krishnan, K | 1 |
| Lee, JY | 1 |
| Sakimura, K | 1 |
| Martin, FC | 1 |
| Quesada, A | 1 |
| Mareš, P | 1 |
| Choudhury, ME | 1 |
| Moritoyo, T | 1 |
| Kubo, M | 1 |
| Kyaw, WT | 1 |
| Yabe, H | 1 |
| Nishikawa, N | 1 |
| Nagai, M | 1 |
| Matsuda, S | 1 |
| Nomoto, M | 1 |
| Costa, C | 1 |
| Tozzi, A | 1 |
| Siliquini, S | 1 |
| Galletti, F | 1 |
| Cardaioli, G | 1 |
| Tantucci, M | 1 |
| Pisani, F | 1 |
| Calabresi, P | 1 |
| Ueda, Y | 2 |
| Tokashiki, S | 1 |
| Kanemaru, A | 1 |
| Kojima, T | 1 |
| Doi, T | 1 |
| Tokumaru, J | 1 |
| Willmore, LJ | 1 |
| Gluck, MR | 1 |
| Santana, LA | 1 |
| Granson, H | 1 |
| Yahr, MD | 1 |
| Tanabe, M | 2 |
| Sakaue, A | 1 |
| Takasu, K | 1 |
| Honda, M | 1 |
| Ono, H | 2 |
| Onodera, K | 1 |
| Kuribayashi, Y | 1 |
| Takahashi, A | 1 |
| Borowicz, KK | 1 |
| Luszczki, JJ | 1 |
| Sobieszek, G | 1 |
| Ratnaraj, N | 1 |
| Patsalos, PN | 1 |
| Czuczwar, SJ | 1 |
| Takeuchi, Y | 1 |
| Owen, AJ | 1 |
| Ijaz, S | 1 |
| Miyashita, H | 1 |
| Wishart, T | 1 |
| Howlett, W | 1 |
| Shuaib, A | 1 |
| White, HS | 1 |
| Leppik, IE | 1 |
| Nagatomo, I | 2 |
| Akasaki, Y | 2 |
| Uchida, M | 2 |
| Tominaga, M | 2 |
| Hashiguchi, W | 2 |
| Takigawa, M | 2 |
| Hamada, K | 1 |
| Song, HK | 1 |
| Ishida, S | 1 |
| Yagi, K | 1 |
| Seino, M | 1 |
3 reviews available for zonisamide and Disease Models, Animal
| Article | Year |
|---|---|
Zonisamide in the treatment of epilepsy.
Topics: Adult; Animals; Anticonvulsants; Clinical Trials as Topic; Compassionate Use Trials; Disease Models, | 2010 |
Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Epilepsies, Partial; Felbamate; Fru | 1999 |
Zonisamide.
Topics: Adult; Animals; Anticonvulsants; Clinical Trials as Topic; Disease Models, Animal; Drug Administrati | 1999 |
35 other studies available for zonisamide and Disease Models, Animal
| Article | Year |
|---|---|
Discovery of benzothiazine derivatives as novel, orally-active anti-epileptic drug candidates with broad anticonvulsant effect.
Topics: Administration, Oral; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, | 2015 |
Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Ep | 2017 |
N-alkyl-[1,1'-biphenyl]-2-sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsy; Mice; | 2017 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Zonisamide ameliorates progression of cervical spondylotic myelopathy in a rat model.
Topics: Animals; Cervical Vertebrae; Disease Models, Animal; Disease Progression; Female; Motor Neurons; Rat | 2020 |
Zonisamide ameliorates neuropathic pain partly by suppressing microglial activation in the spinal cord in a mouse model.
Topics: Animals; Anticonvulsants; Cytokines; Disease Models, Animal; Hyperalgesia; Male; Mice; Microglia; Ne | 2020 |
A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Electroshock; Epilepsy; Free Radicals; Inflammatio | 2018 |
Study the effects of zonisamide on fine structure of rabbit basilar artery and hippocampus in rabbit subarachnoid hemorrhage model.
Topics: Animals; Basilar Artery; Disease Models, Animal; Hippocampus; Isoxazoles; Male; Rabbits; Subarachnoi | 2013 |
Zonisamide: Antihyperalgesic efficacy, the role of serotonergic receptors on efficacy in a rat model for painful diabetic neuropathy.
Topics: Animals; Anticonvulsants; Carbamazepine; Diabetic Neuropathies; Disease Models, Animal; Dose-Respons | 2014 |
Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cell Count; Dependovirus; Disease Models, Animal; Dopaminergic Neurons; Is | 2014 |
Zonisamide attenuates hyperoxia-induced apoptosis in the developing rat brain.
Topics: Animals; Animals, Newborn; Apoptosis; Brain; Disease Models, Animal; Hyperoxia; Immunohistochemistry | 2014 |
Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Cell Death; Cell Line, Tumor; Cell Survival; Disease | 2015 |
Synergism of perampanel and zonisamide in the rat amygdala kindling model of temporal lobe epilepsy.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; | 2016 |
Effects of zonisamide on c-Fos expression under conditions of tacrine-induced tremulous jaw movements in rats: a potential mechanism underlying its anti-parkinsonian tremor effect.
Topics: Animals; Anticonvulsants; Brain; Cell Count; Disease Models, Animal; Dose-Response Relationship, Dru | 2009 |
Zonisamide: in Parkinson's disease.
Topics: Animals; Antioxidants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration | 2009 |
The usefulness of olfactory bulb kindling as a model for evaluation of antiepileptics.
Topics: Amygdala; Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Disease Models, Animal; Electri | 2010 |
The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antioxidants; Corpus Striatum; Diseas | 2010 |
Neuroprotective effects of zonisamide target astrocyte.
Topics: Animals; Antiparkinson Agents; Astrocytes; Basal Ganglia; Carbidopa; Cells, Cultured; Disease Models | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease M | 2010 |
T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor.
Topics: Analysis of Variance; Animals; Benzimidazoles; Calcium Channel Blockers; Calcium Channels, T-Type; C | 2010 |
Zonisamide suppresses the tonic phase but not the clonic phase of generalized seizures in developing rats.
Topics: Animals; Animals, Newborn; Anticonvulsants; Disease Models, Animal; Incidence; Isoxazoles; Male; Rat | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease M | 2010 |
Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity.
Topics: Analysis of Variance; Animals; Antioxidants; Brain; Chromatography, High Pressure Liquid; Disease Mo | 2011 |
A critical role of NO/cGMP/PKG dependent pathway in hippocampal post-ischemic LTP: modulation by zonisamide.
Topics: Animals; Anticonvulsants; Brain Ischemia; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Disease | 2011 |
Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Therap | 2012 |
Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures.
Topics: Amino Acid Transport System X-AG; Amygdala; Animals; Anticonvulsants; Blotting, Western; Carrier Pro | 2003 |
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; | 2004 |
Centrally mediated antihyperalgesic and antiallodynic effects of zonisamide following partial nerve injury in the mouse.
Topics: Animals; Antioxidants; Central Nervous System; Disease Models, Animal; Dose-Response Relationship, D | 2005 |
[An animal model of antiepileptic-induced osteoporosis in rats].
Topics: Animals; Anticonvulsants; Bone Density; Disease Models, Animal; Isoxazoles; Osteoporosis; Phenytoin; | 2006 |
Interactions between zonisamide and conventional antiepileptic drugs in the mouse maximal electroshock test model.
Topics: Animals; Anticonvulsants; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Models, Ani | 2007 |
The supraspinally mediated analgesic effects of zonisamide in mice after peripheral nerve injury are independent of the descending monoaminergic system.
Topics: Analgesics; Animals; Biogenic Monoamines; Chromatography, High Pressure Liquid; Disease Models, Anim | 2007 |
Zonisamide as a neuroprotective agent in an adult gerbil model of global forebrain ischemia: a histological, in vivo microdialysis and behavioral study.
Topics: Animals; Anticonvulsants; Behavior, Animal; Disease Models, Animal; Gerbillinae; Glutamic Acid; Hipp | 1997 |
Effects of combined administration of zonisamide and valproic acid or phenytoin to nitric oxide production, monoamines and zonisamide concentrations in the brain of seizure-susceptible EL mice.
Topics: Animals; Anticonvulsants; Biogenic Monoamines; Brain; Disease Models, Animal; Drug Interactions; Dru | 2000 |
Alterations of nitric oxide and monoamines in the brain of the EL mouse treated with phenobarbital and zonisamide.
Topics: Animals; Anticonvulsants; Biogenic Monoamines; Brain; Disease Models, Animal; Drug Therapy, Combinat | 2001 |
Contrasting effects of zonisamide and acetazolamide on amygdaloid kindling in rats.
Topics: Acetazolamide; Amygdala; Animals; Anticonvulsants; Carbonic Anhydrase Inhibitors; Disease Models, An | 2001 |